Sarsia Seed portfolio company BerGen Bio was today listed on Oslo Stock Exhange. Sarsia Seed was the first investor in the newly established BerGen Bio back in 2010 and has since then invested a total of NOK 20 mill (€...
Les mer
Sarsia Seed’s new seed fund was today officially launced by The Minister of Trade and Industry, Monica Mæland. The size of the fund is € 33 mill and it will be managed by the team in Sarsia Seed Management. The...
Les mer
Vaccibody AS announces vaccination of first patient in its phase IIa study with VB10.16 immunotherapy for patients with HPV16 induced high grade lesions of the cervix. Read more
Les mer
BerGenBio has newly announced its intention to launch an Initial Public Offering and apply for a listing on Oslo Børs. The IPO process will be co-ordinated jointly by ABG Sundal Collier, Arctic Securities and DNB Markets. Sarsia Seed was the...
Les mer
Pharmacies could do much more than they do today says CEO of Boots.  Sarsia Seed portfolio company Screen Cancer is at the core of this strategy. ‘Pharmacies could do much more than what they do today,’ says Stefano Pessina the...
Les mer
A pediatric research group at Haukeland University Hospital in Bergen recently published a scientific paper based on data from clinical study where Volusense Pediatrics was applied to measure lung function in newborns. The article the was published in  European Respiratory...
Les mer
The Sarsia Seed portfolio company Vaccibody has sucessfully completed private placement of NOK 220m (€24m).  The placement was significantly oversubscribed.  This values the company to NOK 600m (€67m) post placement.  Sarsia Seed as the very first investor is still the...
Les mer
Vaccibody announces positive results from the Phase I part of the clinical trial VB C-01 in patients with high-grade cervical dysplasia and recommendation by the Cohort Review Committee as well as the independent data monitoring board to continue to the...
Les mer
Vaccibody AS has announced the successful enrolment of all twelve patients required for the phase I part of the multicentre trial VB C-01 – an exploratory, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade...
Les mer
BerGenBio AS (“BerGenBio” or the “Company”) has announced that it has secured a capital raise of NOK212 million (c. $25 million) in a private placement from existing shareholders, including Investinor AS and Meteva AS.  The proceeds will be used primarily...
Les mer
In collaboration with Idaho National Laboratories (USA) Windsim has developed an unique technology for dynamical assessment of transmission capacity for power lines based on cooling by wind. Windsim has developed a module to the software that calculates in high detail...
Les mer
Vaccibody has received a grant up to € 2 million over four years from the Norwegian Research Council ‘s BIA Program to develop therapeutic cancer vaccines based on each patient’s specific neoantigens. Read more
Les mer
Sorbwater’s pilot project for cleaning of produced water from Middle East oil production receives attention in Waterworld. Read more
Les mer
The CEO of BerGen Bio, Richard Godfrey, was recently interviewed on the online channel Pharma Television. In the interview Godfrey speaks about the company and the cancer drug candidates under development by the company. See more
Les mer
Sarsia Seed Management has received a mandate to establish a new fund for investment in early phase technology-based companies. The size of the fund will be € 33 mill and half of the capital will come from the Norwegian government...
Les mer
A new scientific paper published in Acta Paediatrica by Mariann Bentsen and her co-workers at Haukeland University Hospital confirms that Volusense Pediatrics’ new instrument for non-invasive spirometric measurements when applied on preterm newborns, gives as accurate results as traditional invasive...
Les mer
ScreenCancer’s pilot project for a mole scanning service in UK through pharmacy chain Alphega is covered in local Essex newspaper. Read more
Les mer
APIM Therapeutics appoints Martin Welschof Ph.D to its Board of Directors. Martin, currently serving as the CEO of Opsona Therapeutics, adds significant development and commercialization expertise to the Board of APIM Therapeutics.
Les mer
Vaccibody AS announced today vaccination of the first patient in its multicentre trial VB C-01 – an exploratory, open-label, multicenter phase I/IIa study VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused by human papillomavirus...
Les mer
Last week BerGenBio was awarded one of this year’s Nordic Stars Awards at the Nordic Life Science Days 2015 conference held in Stockholm on 9-10 September. BerGenBio was presented with the award in recognition of its market-leading innovation and entrepreneurial...
Les mer